PFE · News · 20260910N

Licensing / Collaboration Deals

PFIZER INC · 2026-09-10 · Importance 31 · Surprise 42 · In source text

Pfizer has selected its first development field for Novavax’s Matrix-M adjuvant platform. The collaboration could generate milestone payments for combination-vaccine trials and manufacturing-technology transfer, although no payment amount or timing was reported. Novavax identified Pfizer’s Matrix-M collaboration as a near-term catalyst while shifting toward a partnership-driven vaccine strategy.

Key facts

• Pfizer has selected its first Matrix-M development field, offering significant milestone opportunities according to Novavax coverage. source
• The article states Pfizer's guidance is reaffirmed and raised. source
• Pfizer's acquired assets are compounding at 18% operationally. source
• The article cites Pfizer's pipeline strength in obesity (berobenatide) and Vyndamax. source
• Pfizer's P/E is 9.11 as reported in the article. source
• Pfizer's EV/EBITDA is 8.29 as reported in the article. source
• Pfizer's dividend yield is 6.19% as reported in the article. source

Impact estimates